LENSAR to Participate in Two Upcoming Investor Conferences
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in advanced laser solutions for cataract treatment, has announced its participation in two upcoming investor conferences. The company will be part of the H.C. Wainwright 26th Annual Global Investment Conference, offering an on-demand presentation available from September 9, 2024, at 7:00 a.m. Eastern Time. Additionally, LENSAR management will attend the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on September 12, 2024, in New York, where they will conduct one-on-one meetings with institutional investors.
Investors can access the H.C. Wainwright presentation through the Investors section of LENSAR's website at https://ir.lensar.com. These conferences provide LENSAR with opportunities to showcase its innovative cataract treatment technologies and engage with potential investors.
LENSAR (Nasdaq: LNSR), una azienda globale di tecnologia medica specializzata in soluzioni laser avanzate per il trattamento della cataratta, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda farà parte della 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright, con una presentazione on-demand disponibile a partire dal 9 settembre 2024, alle 7:00 ora orientale. Inoltre, il management di LENSAR parteciperà alla 8ª Conferenza Annuale delle Migliori Idee di Crescita di Lake Street Capital Markets il 12 settembre 2024 a New York, dove condurranno incontri one-on-one con investitori istituzionali.
Gli investitori possono accedere alla presentazione H.C. Wainwright tramite la sezione Investitori del sito web di LENSAR all'indirizzo https://ir.lensar.com. Queste conferenze offrono a LENSAR l'opportunità di mostrare le sue innovative tecnologie per il trattamento della cataratta e di interagire con potenziali investitori.
LENSAR (Nasdaq: LNSR), una compañía global de tecnología médica especializada en soluciones láser avanzadas para el tratamiento de cataratas, ha anunciado su participación en dos próximas conferencias para inversores. La compañía formará parte de la 26ª Conferencia Global de Inversión Anual H.C. Wainwright, con una presentación a demanda disponible a partir del 9 de septiembre de 2024, a las 7:00 a.m. hora del Este. Además, la dirección de LENSAR asistirá a la 8ª Conferencia Anual de Mejores Ideas de Crecimiento de Lake Street Capital Markets el 12 de septiembre de 2024 en Nueva York, donde tendrán reuniones individuales con inversores institucionales.
Los inversores pueden acceder a la presentación de H.C. Wainwright a través de la sección de Inversores del sitio web de LENSAR en https://ir.lensar.com. Estas conferencias ofrecen a LENSAR oportunidades para exhibir sus innovadoras tecnologías de tratamiento de cataratas y interactuar con potenciales inversores.
LENSAR (Nasdaq: LNSR), 고급 레이저 솔루션을 전문으로 하는 글로벌 의료 기술 회사로 백내장 치료에 주력하고 있습니다. 이 회사는 두 개의 예정된 투자자 회의에 참여할 예정입니다. LENSAR는 H.C. Wainwright 제26회 글로벌 투자 회의의 일환으로 2024년 9월 9일 오전 7시(동부 표준시)부터 볼 수 있는 주문형 프레젠테이션을 제공합니다. 또한, LENSAR 경영진은 2024년 9월 12일 뉴욕에서 개최되는 Lake Street Capital Markets 제8회 연례 최고 아이디어 성장 회의에 참석하여 기관 투자자들과 일대일 회의를 진행할 예정입니다.
투자자는 LENSAR의 웹사이트 https://ir.lensar.com의 투자자 섹션을 통해 H.C. Wainwright 프레젠테이션에 접근할 수 있습니다. 이 회의는 LENSAR에게 혁신적인 백내장 치료 기술을 선보이고 잠재적인 투자자들과 교류할 기회를 제공합니다.
LENSAR (Nasdaq: LNSR), une entreprise mondiale de technologie médicale spécialisée dans des solutions laser avancées pour le traitement de la cataracte, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise fera partie de la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright, offrant une présentation à la demande disponible à partir du 9 septembre 2024 à 7h00, heure de l'Est. De plus, la direction de LENSAR assistera à la 8ème Conférence Annuelle des Meilleures Idées de Croissance de Lake Street Capital Markets le 12 septembre 2024 à New York, où ils réaliseront des réunions individuelles avec des investisseurs institutionnels.
Les investisseurs peuvent accéder à la présentation H.C. Wainwright via la section Investisseurs du site web de LENSAR à l'adresse https://ir.lensar.com. Ces conférences offrent à LENSAR l'opportunité de présenter ses technologies innovantes de traitement de la cataracte et d'échanger avec des investisseurs potentiels.
LENSAR (Nasdaq: LNSR), ein globales Medizintechnologieunternehmen, das sich auf fortschrittliche Laser-Lösungen zur Behandlung von Katarakten spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird Teil der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright sein, die ab dem 9. September 2024 um 7:00 Uhr Eastern Time als On-Demand-Präsentation verfügbar sein wird. Darüber hinaus wird das Management von LENSAR an der 8. jährlichen Best Ideas Growth Conference von Lake Street Capital Markets am 12. September 2024 in New York teilnehmen, wo sie Einzelgespräche mit institutionellen Investoren führen werden.
Investoren können die H.C. Wainwright-Präsentation über den Investorenbereich der Website von LENSAR unter https://ir.lensar.com abrufen. Diese Konferenzen bieten LENSAR die Möglichkeit, seine innovativen Technologien zur Behandlung von Katarakten vorzustellen und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
-
H.C. Wainwright 26th Annual Global Investment Conference
On-demand presentation available Monday, September 9, 2024 at 7:00 a.m. Eastern Time.
-
Lake Street Capital Markets 8th Annual Best Ideas Growth Conference
Management will conduct one-on-one meetings with institutional investors on September 12, 2024 inNew York .
The on-demand H.C. Wainwright presentation will be available beginning at 7:00 a.m. Eastern Time on Monday, September 9, 2024 and can be accessed through the Investors section of the Company's website at https://ir.lensar.com.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its ALLY® Adaptive Cataract Treatment System as a compact, highly ergonomic system utilizing an extremely fast dual-pulse laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903072207/en/
Thomas R. Staab, II, CFO
ir.contact@lensar.com
Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com
Source: LENSAR, Inc.
FAQ
What investor conferences will LENSAR (LNSR) participate in during September 2024?
When will LENSAR's (LNSR) on-demand presentation be available for the H.C. Wainwright conference?
Where can investors access LENSAR's (LNSR) H.C. Wainwright conference presentation?
What type of meetings will LENSAR (LNSR) conduct at the Lake Street Capital Markets conference?
